Ekta Kapoor, M.B.B.S.

Closed for Enrollment

• A Randomized Double-blind Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study II) (E4Comfort) Rochester, Minn.

  The purpose of this two-part study is to evaluate the effect of 15 or 20 mg of Estetrol (E4), or placebo, on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and the safety of E4 20 mg (Safety Study Part) in postmenopausal women.

• Hormones and Experiences of Aging (HERA): The Mayo Clinic Registry of Midlife Women (The HERA Registry) Rochester, Minn., Scottsdale/Phoenix, Ariz., Eau Claire, Wis., Jacksonville, Fla.

  The purpose of this study is to establish a data repository of peri- and postmenopausal women receiving primary care at Mayo clinic sites.  This collection of data will be from retrospective review of medical records along with prospective surveys completed by subjects.

• Impact of Individualized Estrogen Therapy on Cardiovascular Disease Risk Parameters in Young Women after Bilateral Oophorectomy: A Randomized Controlled Trial Rochester, Minn.

  The purpose of this study is to compare the cardiovascular function in young women (<46 years) following bilateral oophorectomy who are treated with either the standard dose of estradiol (100 mcg transdermal patch or equivalent oral dose) or titrated estradiol dosing to achieve average premenopausal estradiol level (80-120 pg/ml), to characterize the relationship between the serum estradiol level and cardiovascular function in young women (<46 years) on estradiol replacement after bilateral oophorectomy, and to compare the body composition in young women following bilateral oophorectomy who are treated with either the standard dose of estradiol (100 mcg transdermal patch or equivalent oral dose) or titrated estradiol dosing to achieve average premenopausal estradiol level (80-120 pg/ml).

• Mayo Clinic Digital Menopause Management Study Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz., Eau Claire, Wis.

  The purpose of this study is to test a digital health tool developed collaboratively by Mayo Clinic inverstigators and a digital health company to improve the meopause experience of midlife women.